BioFire Diagnostics, LLC, Salt Lake City, Utah, USA; College of Pharmacy, University of Utah Health, Salt Lake City, Utah, USA.
BioFire Diagnostics, LLC, Salt Lake City, Utah, USA.
Diagn Microbiol Infect Dis. 2021 Nov;101(3):115476. doi: 10.1016/j.diagmicrobio.2021.115476. Epub 2021 Jul 1.
Among critically ill COVID-19 patients, bacterial coinfections may occur, and timely appropriate therapy may be limited with culture-based microbiology due to turnaround time and diagnostic yield challenges (e.g. antibiotic pre-exposure). We performed a systematic review and meta-analysis of the impact of BioFire® FilmArray® Pneumonia Panel in detecting bacteria and clinical management among critically ill COVID-19 patients admitted to the ICU. Seven studies with 558 patients were included. Antibiotic use before respiratory sampling occurred in 28-79% of cases. The panel incidence of detections was 33% (95% CI 0.25 to 0.41, I=32%) while culture yielded 18% (95% CI 0.02 to 0.45; I=93%). The panel was associated with approximately a 1 and 2 day decrease in turnaround for identification and common resistance targets, respectively. The panel may be an important tool for clinicians to improve antimicrobial use in critically ill COVID-19 patients.
在危重症 COVID-19 患者中，可能会发生细菌合并感染，由于培养相关的微生物学存在周转时间和诊断产量方面的挑战（例如抗生素暴露前），及时适当的治疗可能会受到限制。我们对 BioFire® FilmArray® Pneumonia Panel 在 ICU 收治的危重症 COVID-19 患者中检测细菌和临床管理方面的影响进行了系统评价和荟萃分析。纳入了 7 项研究共 558 例患者。在进行呼吸道样本采集前，有 28-79%的患者使用了抗生素。该检测面板的检出率为 33%（95%CI 0.25 至 0.41，I=32%），而培养的检出率为 18%（95%CI 0.02 至 0.45；I=93%）。该检测面板分别使鉴定和常见耐药靶标的周转时间缩短了约 1 天和 2 天。该检测面板可能是临床医生改善危重症 COVID-19 患者抗菌药物使用的重要工具。
